Related Experiment Video
Updated: Aug 8, 2026

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation
Published on: May 2, 2013
[Local immune tolerance mechanisms in kidney cancer]
Jean-Jacques Patard1, Françoise Bouet, Nathalie Rioux-Leclercq
1Service d'Urologie, CHU Pontchaillou, Rennes, France. jean-jacques.patard@chu-rennes.fr
Abstract:
Many arguments suggest that renal tumours are immunogenic. However, the immune cells present around or within the tumour are unable to induce tumour rejection and the results of immunotherapy in metastatic renal cancer remain disappointing regardless of the protocols used. The objective of this study was to review the main mechanisms by which a renal tumour can escape immune destruction. These mechanisms can concern: tumour antigens, antigen-presenting molecules on the cell surface or defects of the cell machinery leading to the preparation of these molecules. Defects may also concern intercellular communications, especially adhesion and co-stimulation molecules. The immune cells present may also be defective, presenting qualitative or quantitative deficits, abnormalities of the T receptor, defect of cytokine production and these defects may concern both effector cells and antigen-presenting cells. The capacity of tumour cells to release anergic substances, i.e. substances which paralyze the immune system, also constitutes another very powerful immunosuppressive mechanism. These substances are cytokines, especially TGF-b. This anergy can also be mediated by intercellular contacts between tumour cells and lymphocytes, especially via the Fas system. It is important to study these mechanisms for several reasons: 1/Understanding of anergy mechanisms in order to discover new therapeutic targets or to short-circuit these mechanisms in vitro; 2/Definition of an "immune phenotype" of the tumour which should be evaluated as a prognostic marker both for survival after radical surgery of localized tumours as a prognostic factor for response to immunotherapy in metastatic forms.
Insights
Renal tumors evade immune destruction through various mechanisms, hindering effective immunotherapy. Understanding these escape routes is crucial for developing better cancer treatments and prognostic markers.
Area of Science:
- Oncology
- Immunology
Context:
- Renal tumors are immunogenic, yet immune cells fail to reject them.
- Immunotherapy for metastatic renal cancer yields disappointing results.
Purpose:
- To review the primary mechanisms by which renal tumors escape immune destruction.
- To identify targets for novel therapeutic strategies and prognostic markers.
Summary:
- Tumor escape mechanisms involve defective tumor antigens, antigen presentation, intercellular communication (adhesion/co-stimulation molecules), and immune cell deficits (T-cell receptor, cytokine production).
- Tumor cells release immunosuppressive cytokines like TGF-b and utilize cell contact (Fas system) to induce immune anergy.
- Evaluating the tumor's "immune phenotype" may serve as a prognostic marker for survival and immunotherapy response.
Impact:
- Informing the development of novel therapeutic targets to overcome immune evasion.
- Enabling the definition of an "immune phenotype" for prognostic assessment in localized and metastatic renal cancer.
Related Concept Videos
Cell-mediated Immune Responses
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Tumor Immunotherapy
Kidney Transplant I: Introduction
Kidney Transplant II: Surgical Procedure
Kidney Transplant III: Nursing Management

